Vanda Pharmaceuticals (NASDAQ:VNDA) reported interim results from its Phase 3 trial assessing tradipitant for the treatment of COVID-19 pneumonia.
The data are based on the first 60 patients enrolled in the study, who received either tradipitant, a neurokinin-1 receptor antagonist, or placebo.
The interim analysis showed that 57% of patients who received tradipitant improved, compared with 50% of patients who received placebo. The mortality rate of patients who received tradipitant was 14.2%, compared with 16.6% of patients who received placebo.
In the time-to-improvement analysis conducted after seven days of treatment, patients treated with tradipitant recovered earlier than those receiving placebo.
“These results, albeit preliminary, are exciting, offering the promise of a significant contribution in the treatment of COVID-19 and the prospect of making tradipitant part of the standard-of-care in accelerating recovery for patients with COVID-19 pneumonia,” Dr. Mihael Polymeropoulos, Vanda’s president and CEO, said in a statement.
The study is being conducted at New York City’s Lenox Hill Hospital in collaboration with The Feinstein Institutes for Medical Research and is expected to enrol some 300 patients.
